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ABSTRACT
The first phase in the management of mental illnesses requires an intimate
understanding of the thorough side effects of the medications prescribed. The treatment
of antipsychotics involves a unique approach. New technological shifts in the field of
anti-psychotic medications have been revolutionized. While most anti-psychotic
medications are capable of battling psychosis, the effects vary from medication to
medication. The susceptibility of akathisia has significant consequences. Akathisia can be
easily overlooked and passed off as irritability leading to misdiagnosis.
The purpose of the Doctor of Nursing Project (DNP) was to bring awareness to
akathisia and the Barnes Akathisia Rating Scale (BARS). Patients taking anti-psychotics
need an accurate tool to measure their baseline prior to starting anti-psychotics and an
accurate to measure the side effects of anti-psychotics during treatment. The BARS scale
is the solution to accurately measure akathisia symptoms.
The DNP project was conducted in an outpatient clinic in southern Mississippi.
Four hundred thirty-six (436) patients were seen within a 30-day time frame. Of those
436 patients 27 patients presented with symptoms of akathisia. The healthcare providers
at this clinic documented akathisia's symptoms using a narrative note or the Abnormal
Involuntary Movement Scale (AIMS). This scale can mask akathisia symptoms because it
does not distinguish between akathisia and tardive dyskinesia. The two side effects have
very different treatments. It is important to rate the level of severity on abnormal
movement-specific scales. The BARS Scale measures akathisia exclusively.
Participants in the DNP project were given a pre-test, education, and a post-test.
The pre-test tested the knowledge of participants' awareness of akathisia, the BARS
ii

scale, and how they currently document akathisia. The pre-test revealed that 60% of
participants see akathisia on a weekly basis. Most participants documenting akathisia
using a narrative note, while 20% used the AIMS scale to document akathisia. The
education was given in a form of a PowerPoint®. The post-test was scenario-based
patients and required the use of the BARS scale to rate the level of the severity of
akathisia each patient presented with. Participants’ post-tests were compared. The posttest revealed 80% of the participants answered the scenario-based questions similarly.
The post-test proves that the BARS scale validity to measure akathisia.
The findings from this DNP project indicate that there is a need for an akathisia
scale in an outpatient clinical setting. Research revealed that patients taking antipsychotics are distressed due to their akathisia. First episode akathisia patient’s
experience thoughts of suicide (Salem, 2017). Patients usually stop taking their
medications due to having thoughts of suicide induced by akathisia. The distress caused
by the side effects of antipsychotics needs to be addressed. The BARS scale is easy to use
tool to measure the baseline of akathisia symptoms and is a tool that can be used
throughout the treatment of antipsychotic use. The BARS scale aids in the early detection
and treatment of akathisia. Early treatment of akathisia lessens the patients’ feelings of
distress and increases the chances of medication compliance.
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CHAPTER I - INTRODUCTION
While working many years in mental health when reviewing charts, it appeared
routine to see that each patient had a history and physical exam along with an AIMS
(Abnormal Involuntary Movement Scale) scale assessment. AIMS scale exclusively
favors the measures for tardive dyskinesia. Tardive dyskinesia is a condition that affects
the nervous system caused by the long-term use of neuroleptic/anti-psychotic
medications. Throughout the years of caring for mental health patients’ tardive dyskinesia
was rarely seen in acute care settings or outpatient settings. Tardive dyskinesia was
mostly seen in long-term care mental health facilities like a forensic hospital. Akathisia,
however, was a more common side effect of antipsychotic use that was seen often.
Akathisia is a feeling of muscle quivering, restlessness, and inability to sit still. Akathisia
can be very distressing to the patient and can be misdiagnosed and passed off as agitation
(Hirose, 2003). There should be a scale incorporated into the initial mental health
assessment to measure the baseline symptoms of akathisia. The BARS (Barnes Akathisia
Rating Scale) scale measures the severity of akathisia symptoms. This scale aids in the
early detection and treatment of akathisia and rids the patient of distress, potential
noncompliance with medication, and declining health.
Background and Significance
Akathisia is a common side effect of antipsychotics that can go unrecognized to
the untrained eye and can be overlooked by a trained healthcare professional. It is
important to be direct when asking patients questions about akathisia. Patients often feel
inner restlessness or a sudden urge to move. They may be seen squirming or fidgeting
intermittently. It is important to educate the patient on these side effects and follow up
1

with an akathisia questionnaire each visit. PHMNP and Psychiatrists can easily overlook
akathisia due to a lack of objective findings.
The BARS scale was originally created thirty years ago and are one of the most
underutilized akathisia scales created. Its’ validity and reliability have been established
worldwide. The Turkish created a version of the BARS scale to help with the diagnosis of
akathisia and to provide an objective tool for researching akathisia (Bayram et al., 2017).
The Turkish used five physicians and forty patients with schizophrenia who were taking
anti-psychotics for their study. The results shown from each patient were positive for
akathisia and the study rated the BARS scale as a reliable tool to use to measure akathisia
(Bayram et al., 2017).
The AIMS scale is currently used to measure akathisia and tardive dyskinesia.
The AIMS scale can mask symptoms of akathisia. The AIMS scale particularly favors
tardive dyskinesia. The numerical value at the end of the AIMS scale does not distinguish
which abnormal movement is rated. Both abnormal movements are induced by antipsychotics but are treated very differently, for this reason, an akathisia scale should be
used to rate akathisia accurately.
Problem Statement/Clinical Question (PICOT)
(P) In mental health patients ages, 18-64 taking antipsychotic medications,
visiting a mental health clinic setting experiencing akathisia symptoms. (I) does use
akathisia measuring scale to properly assess and rate the level of severity of akathisia. (C)
compared to using an AIMS scale which favors tardive dyskinesia. (O) Offer earlier
detection of akathisia symptoms.
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Project Purpose
This research aims to assess akathisia in a clinical setting. Proper understanding
of akathisia can lead to recognition, early detection, and treatment of akathisia. The study
seeks to explain the severity and the issues related to this psychotropic drug-induced
disorder. To assess the severity of akathisia, the clinician must first be familiar with the
condition and be familiar with the akathisia scale to accurately measure its presentation.
This research aims to bring recognition to the Barnes Akathisia Rating Scale (BARS).
The BARS scale was created in 1989 and was revisited in 2003. This scale is the most
accurate in comparison to the only other documented scale found to solely measure antipsychotic induced akathisia, the Hillside Akathisia Scale (HAS). The BARS scale is very
useful in systematically assessing patients with akathisia, rating their severity, and
monitoring their change in symptoms.
Objective and Expected Outcomes
The objective outcomes are to teach healthcare providers about the Barnes
Akathisia Rating Scale and bring awareness to the mental distress akathisia may cause to
patients. The expected outcomes are to incorporate the Barnes Akathisia Rating Scale
into the initial mental health assessment and revisit the scale for follow-up visits with
patients that are taking anti-psychotics.
Theoretical Framework
Akathisia can take place days to weeks after the initial start of an anti-psychotic or
after an increased dose of an anti-psychotic (Salem et al., 2017). Tardive dyskinesia
usually occurs 1-3 months after the start of treatment (Salem et al., 2017). Currently,
physicians, nurse practitioners, and physician assistants are conducting AIMS scores on
3

every mental health patient. Since AIMS measures abnormal movements and akathisia is
considered an abnormal movement, akathisia measurements can be measured on numbers
5, 6, 8, 9, and 10 of the AIMS scales (Menzies & Farrell, 2002). These numbers on the
AIMS scale measure extremity movements and global judgments, but in relation to
tardive dyskinesia, not akathisia. The other questions focus on orofacial movements,
trunk movements, and dental status which are symptoms are tardive dyskinesia. This
scoring method does not solely address akathisia and can mask akathisia ratings.
Akathisia is a more common side effect seen today with the use of multiple secondgeneration anti-psychotics (Salem et al., 2017). Patients on more than one secondgeneration anti-psychotic had an increase of 34.2% vs 10.9% on experiencing akathisia
(Salem et al., 2017). The BARS scale would be a more appropriate and more accurate
approach to measuring akathisia symptoms and tracking the progression of decline in
symptoms throughout treatment. The BARS scale is a simple solution to capturing
akathisia symptoms. If akathisia symptoms go unnoticed it can lead to an emergency,
especially since akathisia is related to increased thoughts of suicide and increased
thoughts of aggression and violence (Salem et al., 2017). Anti-psychotics tend to cause
more weight gain and thus contribute to cardiovascular disease in patients with
schizophrenia. Patients with schizophrenia tend to have heart disease due to poor eating
habits, sedentary lifestyles, and smoking.
DNP Essentials
DNP Essential III, Clinical Scholarship Analytical Methods for Evidence-Based
Practice details the DNP graduates’ role in assuring accountability of quality care and
patient safety. This DNP essential allows DNP graduates to facilitate the skills of
4

organization-wide changes that are patient-centered (Spencer, 2019). DNP Essential III
best describes this project because it supports quality care and patient safety. The
implementation of the akathisia scale during the initial mental health assessment offers a
baseline for each patient being started on an anti-psychotic. If the patient has any
abnormal movement like a tic or tremor before starting an anti-psychotic this scale will
rate the tremor as such and give a baseline rating as the patient presents before treatment.
There will be no confusion on the level of severity of akathisia due to taking
antipsychotic medication. When the patient begins psychotropic treatment, there will data
to show when the patient's akathisia symptoms started, without giving a false rating or
narrative. DNP Essential III suggests that the findings of evidence-based practice be used
to improve healthcare outcomes (Spencer, 2019). The BARS scale will be used to detect
and treat akathisia at its early stages. Implementing the BARS scale improves patient
outcomes and decreases the length of time a patient could experience such debilitating
side effects.
DNP Essential VI, Interprofessional Collaboration for Improving Patient and
Population Health Outcomes enforces the need for patient care to be a team-based
approach. This DNP essential exhibits how thorough effective communication and
collaboration with patient care and patient outcomes are priority (Spencer, 2019). DNP
Essential VI relates to this DNP project topic because it references a team-based
approach. Patients can be cared for by multiple providers or may choose to switch
providers. In doing so, through electronic charting multiple providers have access to
patients’ electronic medical records. Electronic charting allows for easy access to the
patients’ charts. Continuity of care is an important aspect to point out with this project.
5

Through the use of the BARS scale, it allows patient outcomes and improvement of
akathisia symptoms to be easily transferred. The severity of akathisia last documented on
the patient can be used as a resource for the level of severity of akathisia in the patient
viewed by the new clinician. Through collaboration, providers can view the patient's
progress of treatment with the use of the BARS scale.
Needs Assessment
The author conducted a needs assessment at a southern Mississippi behavioral
health clinic. The clinic was proven to have a need for an akathisia project according to
the data provided by the clinic’s nurse practitioners. There were 436 patients seen by the
provider within 30 days. Within the 30-day time frame, 27 of the 436 patients were
reported to have akathisia symptoms. The patient’s akathisia symptoms were recorded in
a narrative note or using the AIMS scale. The AIMS scale revealed a numerical value that
distinguished abnormal movement. The AIMS scale numerical value does not specify
which abnormal movement is present. The BARS scale would be better in identifying the
level of severity of akathisia symptoms without being masked by EPS other symptoms.
Synthesis of Evidence
Anti-psychotic induced akathisia is a truly relevant topic. Attention was first
bought to akathisia in 1961 (Turk et al., 2018). The common side effect of akathisia can
cause a stigmatizing effect on patients leading them to depression, medication
noncompliance, and potential debilitating psychosis (Bjarke et al., 2020). Suicidality is
related to akathisia symptoms as well. The supportive text notes that the first episode of
akathisia patients had an increased risk of possible suicide (Bjarke et al., 2020).
Abnormal movement symptoms were thought to decrease with the use of second6

generation antipsychotics (SGA) also known as atypical antipsychotics, but a substantial
number of patients treated with atypical anti-psychotics still experience akathisia (Bjarke
et al., 2020).
There are scales available to measure akathisia. The scales are not utilized to their
full potential. Most clinicians are not aware that these scales exist. The BARS scale is a
short but thorough scale that measures akathisia symptoms. This scale is easy to
incorporate into daily assessments. The AIMS scale used during initial mental health
assessment does not favor symptoms we see today with the use of atypical antipsychotics. Adding the BARS scale would make a huge difference and impact the way
clinical notes are viewed for patients that present with akathisia symptoms. The BARS
scale would make comparing akathisia symptoms from a visit to visit easier. If clinicians
alternated care, the BARS scale would allow transparency of akathisia symptoms from
the previous visit, making it easier to make changes to medications seamlessly.
Akathisia and restless leg syndrome share some similarities. Restless leg
syndrome is characterized by an irritable sensation in the legs that is relieved by
movement and occurs more often in the late afternoon or evening (Turk et al., 2020).
Restless and crawling sensations can also be a symptom of akathisia except it would not
fluctuate like restless leg syndrome (Turk et al., 2020). There are symptoms that persist in
both disorders that make the two easily confused. The clinician must be able to
distinguish the two disorders to properly treat the patient. The BARS scale could be
helpful for use of rating akathisia symptoms and distinguishing the difference between
akathisia and restless leg syndrome.
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Focused Topics and Evidence-Based Findings
The BARS scale is centered around akathisia symptoms. It is an easy tool to add
to an initial assessment to get a baseline of akathisia symptoms. An AIMS scale
exclusively measures tardive dyskinesia. Although an AIMS scale asks a few questions
that pertain to abnormal movement in the extremities, this does not suffice for a
commonly overlooked symptom like akathisia. According to Hirose, there are two major
reasons why akathisia may be overlooked and underdiagnosed (2003). The first reason is
the inability to fulfill diagnostic criteria for akathisia and the second reason is conditions
that do not fulfill diagnostic criteria but can still benefit from anti-akathisia interventions
that are underdiagnosed (Hirose, 2003). Clinicians are less worried about akathisia since
atypical anti-psychotics are said to produce fewer extrapyramidal side effects (EPS)
(Hirose, 2003). Akathisia and other EPS side effects still exist with the use of atypical
anti-psychotics. Literature notes that of the six anti-psychotics available for prescription,
risperidone and olanzapine are the two that show lower signs of EPS. These symptoms
can worsen when the doses are increased (Farah, 2013). Farah notes that the biggest
concern with akathisia comes from the atypical anti-psychotic, aripiprazole (Farah,
2013). It is noted that most akathisia patients do not volunteer the information of inner
restlessness until the term is explained to them. Motor restlessness is objectively seen and
can be rated as such, but inner restlessness is subjective, and the patient would need to be
questioned by the clinician for confirmation (Hirose, 2003).
Rationale-Framework, Models, Concepts/Theories
The problem persists that akathisia is a distressing side effect of anti-psychotic
use that can lead to thoughts of suicide and non-compliance with medication. If clinicians
8

assess akathisia symptoms early on, this problem can be addressed and eliminated. The
way to eliminate this problem is to add an akathisia scale to the initial mental health
assessment and future mental health assessments. The AIMS score is captured on the
initial mental health visit. The AIMS scale measures for EPS symptoms like tardive
dyskinesia, not exclusively akathisia. The AIMS score may mask the true rating of
akathisia. If the BARS scale was present to assess and rate akathisia, patients’ symptoms
would be detected and treated sooner which will eliminate the distressing feeling patients
have and eliminate or decrease suicidal thoughts related to impending restlessness related
to akathisia.
Summary
In summary, akathisia is a reversible movement disorder that when diagnosed
early can save the patient from having feelings of irritability, distress, and suicidal
thoughts (Salem et al., 2017). Early diagnosis will also aid in medication compliance.
Akathisia is one of the most common side-effects of antipsychotic medications and can
easily be passed off as agitation when presented to a clinician unfamiliar with the
disorder (Salem et al., 2017). The BARS scale is an easy rating scale used to measure
akathisia. The scale is short, which is a great incentive to clinicians that are often on a
time restraint. The use of the BARS scale is an easy effective addition to the patients’
assessment. The BARS scale is an asset to patients’ healthcare and well-being when antipsychotics are started, or anti-psychotic doses are increased. The BARS scale is an easy
tool to measure a change in the patient leading to the detection of akathisia. Chapter I
provided the introduction, background, and significance, project purpose, objective and
expected outcomes, theoretical framework, needs assessment, synthesis of evidence,
9

focused topics and evidenced-based findings, and rationale framework. Chapter II will
discuss the methods used to complete this project.
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CHAPTER II – METHODS
The purpose of this Doctor of Nursing Practice (DNP) project was to bring
awareness to akathisia and the Barnes Akathisia Rating Scale (BARS). The use of the
BARS scale would accurately measure akathisia and offer a numerical value that would
range from 0-9. Zero would be no signs of akathisia and the number nine would indicate
severe akathisia. This scale would be used at the start of any anti-psychotic medication
treatment and would also be used at follow-up visits. The use of the BARS scale
ultimately improves the accuracy of the patient’s akathisia symptoms. The BARS scale
offers transparency in the level/rate of the patient presenting with akathisia.
Setting
The DNP Project was conducted in a southern behavioral health Mississippi clinic
located in Poplarville, Mississippi. The clinic sees more than four hundred patients in a
30-day span. The clinic is staffed by two nurse practitioners and two nurses. The
outpatient clinic sees a host of patients beginning at the age of five years old and across
the lifespan. The outpatient clinic provides integrated mental health and behavioral health
services. The number of patients experiencing akathisia in this clinic presented a great
opportunity to offer information about akathisia and an akathisia rating scale.
Population/Sampling
The population of interest consists of mental health patients with schizophrenia
diagnoses. The population included patients ages 18-64. Each of these patients were
prescribed anti-psychotic medication. The study excluded adolescent and geriatric
patients. Out of the four hundred thirty-six (436) patients seen in a thirty (30) day span,
twenty-seven (27) patients of those patients experienced akathisia.
11

Data Collection, Procedures, and Design
A scenario-based case study focused on the literature was performed to classify
trials of atypical anti-psychotics affecting patients ages 18-64 with schizophrenia or
associated conditions (e.g., schizoaffective disorder). The project involved randomized
scenario-based case studies. The scenario-based case study included four detailed
questions related to akathisia presentation in a clinical setting. Data on the evolving
BARS akathisia scale were included. A pre-test was provided to the clinical staff. After
the pre-test, the staff was educated on akathisia and its presentation, along with being
educated on the BARS scale. A post-test was given. The test provided to participants
determined the integrity and validity of the BARS scale. All consents and data collection
were exchanged through a secure email. Most participants chose to print their emails and
hand score each question, while other participants chose to digitally answer their
questions. Each email was sent separately and privately.
Ethical Considerations
This project was submitted to The University of Southern Mississippi IRB
(Protocol # 21-204) for approval. This project did not include the study of any human
subjects; therefore, there were no direct violations of ethical principles. The sole purpose
of this project was to bring awareness to akathisia and implement an akathisia rating
scale.
Data Analysis
Data from this project included a pre-test, which tested the knowledge of the topic
with the participants involved. The pre-test included questions about how the participants
narrate their patients' side effects to antipsychotics. The participants were then educated
12

on the topic and its’ purpose. The education was given to participants in the form of a
PowerPoint®. A post-test was given. The participants' post-test results were compared.
Scores were analyzed using simple mathematical addition.
Summary
After the completion of the project, the test was scored in a secure private room
by the doctoral student. Each test was carefully read and measured by the doctoral
student. The results of the post-test were discussed with the nurses and nurse
practitioners. The data was protected and remained safely stored. The results are
discussed in Chapter III.
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CHAPTER III - RESULTS
The doctoral project met its goal of implementing and integrating the Barnes
Akathisia Rating Scale into the mental health assessment. The participants agreed that the
BARS scale was a more accurate tool to measure akathisia. This doctoral project also
improved the knowledge of akathisia symptoms among the nurses working at this clinic.
The nurse practitioners encouraged the use of the BARS scale as a baseline to measure
for akathisia symptoms, and as a tool to use throughout the treatment of antipsychotic
use.
Analysis of Data
A secure email was used for participants. In this email, participants were given an
invitation to participate in the DNP project. In addition to the initial invitation, consent to
participate in the DNP project was given as well. The participants had to sign the consent
form and email the consent back to the secure email address. The participants were given
a pre-test. The pre-test tested the participant's knowledge of akathisia, tardive dyskinesia,
and their presentation. A question related to the BARS scale was also included in the pretest. The pre-test was given through a secure email and sent back through secure email.
Education was provided via PowerPoint® and sent through secure email. Participants
were given five days to review the education provided on akathisia and the Barnes
Akathisia Rating Scale. After the five days, a post-test was given. The post-test was a
scenario-based clinical study given to participants. The post-test provided included a
total of four scenario-based questions. These questions were sent along with the Barnes
Akathisia Rating Scale. The scale ensured that all participants had all resources needed to
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accurately rate their patient’s severity of akathisia. Participants were to read each
question and rate the level of severity for each scenario-based patient.
Results took a week to come in. There were two occasions where there was data
missing. Two participants did not read the directions carefully and did not use the BARS
scale as directed. These participants were encouraged to re-read the directions and re-take
their post-test using the BARS scale and resend their results via the secure email.
Participants were compliant with resending emails and using the BARS scale to rate the
severity of akathisia.
Results of the pretest revealed that 60% of participants see akathisia on a weekly
basis. All participants knew what akathisia was, most explained akathisia in a note while
20% used AIMS to measure akathisia. The post-test revealed 80% of participants
answered the questions similarly. The post-test proves that the BARS scale is a valid tool
that can be used to accurately measure and rate the level of severity for akathisia.

Figure 1. Scenario-Based Questionnaire Using the Barnes Akathisia Rating Scale.
15

Figure 2. Percentage of Participants that See Akathisia on a Weekly Basis.

Figure 3. Percentage of Participants Reported Using the AIMS Scale to Measure
Akathisia.
16

Summary
The comparison of post-test results revealed that the Barnes Akathisia Rating
Scale (BARS) is an accurate tool. The tool measures akathisia because most participants
answered their scenario-based questions the same. This proves that the measuring tool is
a reliable tool to measure akathisia.
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CHAPTER IV – DISCUSSION
Through implementing an akathisia scale into the mental health assessment, the
akathisia scale offered a baseline of the patients’ level of severity of akathisia. The
participants in the study mostly rated the scenario-based patient questionnaire similarly.
These scores indicated that the use of the BARS scale would be successful and offer
depth and accuracy to the patients’ diagnosis and treatment plan. Results revealed four
out of five participants answered the scenario-based questions similarly. Participants
rating their patient scenarios similarly prove that the BARS scale is effective in rating
akathisia. Offering a baseline of akathisia symptoms can be difficult. Proper education of
the BARS scale and its’ use can allow for transparent symptoms of akathisia between
follow-up visits and/or change in healthcare providers. Healthcare providers agreed that
this addition to their assessment would offer an easier and accurate way to share data on
patients exhibiting akathisia.
Akathisia is one of the most distressing symptoms associated with antipsychotic
medication use. Some patients state the feeling of akathisia is an indescribable feeling
they cannot control. Those patients experiencing akathisia, experience an inability to sit
still and a constant urge to move (Salem et al., 2017). The feeling of inner restlessness
causes the patient to rock while standing or sitting and to constantly move their feet.
Unlike tardive dyskinesia, akathisia mostly deals with lower extremity movement.
Tardive dyskinesia can affect the orofacial muscles, hands, and feet. Akathisia and
tardive dyskinesia are both EPS symptoms, these two side effects are so common.
Different scales should be used to measure akathisia and tardive dyskinesia. With the use
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of different rating scales for akathisia and tardive dyskinesia, there will be no confusion
in the level of severity for each.
Healthcare Professional Role Change (HCP) and Future Role Implications
The author’s role as a healthcare provider changed from being a bedside nurse
and student to making decisions that can alter medication doses, rendering a new
prescription, or decrease/increase in medication. It takes skill and expertise to write
prescriptions. As an aspiring PMNP (psychiatric mental health nurse practitioner), a
combination of higher education and hands-on clinical learning has eased the anxiety of
transitioning quite a bit. Many PMNP has similar responsibilities as a psychiatrist.
Diagnosing, treating, and prescribing psychotropic medications are all a part of treating
mental health patients. The author has grown comfortable in her current role as a staff RN
(registered nurse). She has mastered the daily tasks of nursing and has developed
observation skills as well as the skill to act on instinct. The author currently works
twelve-hour shifts three days a week. A Monday through Friday job as a PMHNP in an
outpatient setting will be a significant change. Sitting, talking, and listening to patients in
a clinical setting for a fifteen-minute interval is a difficult task. The fifteen-minute
intervals will include charting and prescribing as well. The author’s goal is to provide the
best care for every patient all while being an efficient and productive provider.
Interpretation
The BARS scale was used in the implementation of this DNP project because it
helps rate the level of severity of akathisia symptoms. The impact this project has on the
mental health population is great. This project brings awareness to the way akathisia is
documented. The BARS scale allows for accurate measurement of akathisia without
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masking the symptoms. Akathisia can be easily missed or passed off as irritability or
even misdiagnosed as restless leg syndrome. Most results from this DNP study were
answered similarly. Four out of five participants had the same answers. Outcomes may
have been different because the participant may have misread the instructions. Before
starting this project participants were charting a narrative note to describe the patients’
symptoms. Other providers were using the AIMS scale to measure akathisia symptoms.
Using the BARS scale offers transparency to the level of severity of the patient's
symptoms, focusing on akathisia and no other symptom or side effect. In narrative notes,
a way of wording may be confusing or misinterpreted. With the use of the AIMS scale
akathisia symptoms can be masked as well due to other questions that pertain to tardive
dyskinesia. Through the use of the BARS scale the level of severity of akathisia is more
precise. The scale offers a range in severity of akathisia symptoms. If the results of this
project were compared to the results of the Turkish BARS project, it would be
comparable. The Turkish BARS project shows high reliability to the use of the BARS
akathisia scale (Bayram et al., 2017). Through the use of the BARS scale patients’
akathisia symptoms can be rated easily according to their level of severity. By bringing
awareness to the BARS scale and its purpose, healthcare providers can measure akathisia
symptoms earlier and throughout treatment. Patients will experience shorter periods of
distress with the use of the BARS scale, which will aid in medication compliance
ultimately stabilizing the patients’ mental health.
Limitations and Barriers
Limitations to this DNP study included sample size and limitation on using one
facility. If there were more participants, the outcomes may have differed. If an additional
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clinic could have been used to compare patients seen with akathisia, the need for an
akathisia scale may have differed. In other clinic’s there may have been some form of an
akathisia rating scale used that was not incorporated in the clinic where this DNP project
was performed. Many things exist that could have altered the study. Some bias that may
present may relate to using the AIMS scale to measure akathisia. The author firmly
believes that the AIMS scale masks akathisia symptoms. The AIMS scale particularly
favors tardive dyskinesia. The two abnormal movements are very different in
characterization and should be rated separately on different forms of abnormal movement
scales.
Barriers to this study include time constraints and how long the author could hold
the participants' attention with this project. The author had to remind each participant to
answer their email in a timely fashion. Some participants were eager to finish while other
participants needed constant reminders to do so. Other barriers included the inability to
control the participants from searching for data on akathisia during the pretest time frame.
One participant included that they searched for information to answer one of the
questions, which was prohibited.
Conclusions
At the end of this project, participants appreciated the information given on
akathisia and the BARS scale. Participants felt that the BARS scale was much more
relatable to akathisia than the AIMS scale. Akathisia is a known side effect of
antipsychotics, yet participants did not know to which extent patients were suffering. All
participants involved in this project agreed that the BARS scale can easily be
incorporated into each mental health assessment of a patient being started on an
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antipsychotic. Participants also agreed the BARS scale is a great tool to use to measure
akathisia throughout antipsychotic medication treatment.
The sustainability of this project is great in comparison to the Turkish akathisia
project. The conclusion of the DNP project ended with great percentages. Everyone that
participated in the project had similar answers, which proves that the BARS scale is easy
to learn and incorporate in mental health assessments. With such a large percentage of
participants answering the questions similarly, it makes the project impactful and easily
understood. The goal of incorporating the BARS scale was to impact health care without
making it a nuisance to incorporate another document into the mental health assessment.
The BARS scale is an asset. Detecting akathisia at its’ earliest stages before it becomes
debilitating to the patient is the priority.
The BARS scale will be incorporated into the mental health assessments of
patients taking anti-psychotics. The author will share the information about the BARS
scale with those she works with through verbal conversation and handouts. Through
discussion, the author will explain to other providers that while researching an akathisia
rating scale that providers caring for patients with akathisia did not know the extent to
which their patients were suffering. The feeling of internal restlessness leads some
patients to have thoughts of suicide. The uncomfortable feeling akathisia induces is a
huge dilemma that has gone overlooked for too long. Providers need to be aware of the
extent of the mental debilitating factors that can take place with the use of antipsychotics.
If anything could be done differently in this project, it would be to create a new
akathisia scale, incorporating more subjective data questions for the patient. One that
would probably be like the BARS scale with more descriptive symptoms and side effect
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choices. More time could have been spent with the participants, but participants'
schedules were conflicting. An in-person educational presentation on akathisia would
have been ideal, but due to covid, the author felt a contactless free presentation would be
more appropriate and safer for everyone involved.
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APPENDIX A – IRB Approval Letter
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APPENDIX B – Barnes Akathisia Rate Scale
Name:________________________________________

Date:__________________

Instructions: Patients should be observed while they are seated, and then standing while
engaged in neutral conversation (for a minimum of two minutes in each position). Symptoms
observed in other situations, for example, while engaged in activity on the ward, may also be
rated. Subsequently, the subjective phenomena should be elicited by direct questioning.

Objective
Normal, occasional fidgety movements of the limbs
0
Presence of characteristic restless movements: shuffling or tramping movements of the
legs/feet, or swinging of one leg while sitting, and/or rocking from foot to foot or
“walking on the spot” when standing, but movements present for less than half the time
observed
1
Observed phenomena, as described in (1) above, which are present for at least half the
observation period
2
The patient is constantly engaged in characteristic restless movements, and/or cannot
remain seated or standing without walking or pacing, during the time observed

Subjective
Awareness of restlessness
Absence of inner restlessness
Non-specific sense of inner restlessness
The patient is aware of an inability to keep the legs still, or a desire to move the legs,
and/or complains of inner restlessness aggravated specifically by being required to a
standstill
3
Awareness of intense compulsion to move most of the time and/or reports strong desire
to walk or pace most of the time
0
1
2

Distress related to restlessness
0
No distress
1
Mild
2
Moderate
3
Severe
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Global Clinical Assessment of Akathisia

0

1
2

3

4

5

Absent. No evidence of awareness of restlessness. Observation of characteristic
movements of akathisia in the absence of a subjective report of inner restlessness or
compulsive desire to move the legs should be classified as pseudoakathisia
Questionable. Non-specific inner tension and fidgety movements
Mild akathisia. Awareness of restlessness in the legs and/or inner restlessness is worse
when required to stand still. Fidgety movements are present, but characteristic restless
movements of akathisia are not necessarily observed. The condition causes little or no
distress.
Moderate akathisia. Awareness of restlessness as described for mild akathisia above,
combined with characteristic restless movements such as rocking from foot to foot when
standing. A patient finds the condition distressing
Marked akathisia. The subjective experience of restlessness includes a compulsive desire
to walk or pace. However, the patient can remain seated for at least five minutes. The
condition is obviously distressing.
Severe akathisia. The patient reports a strong compulsion to pace up and down most of
the time. Unable to sit or lie down for more than a few minutes. Constant restlessness is
associated with intense distress and insomnia.

Scoring the Barnes Akathisia Rating Scale (BARS)

The Barnes Akathisia Rating Scale is scored as follows:
Objective Akathisia, Subjective Awareness of Restlessness, and Subjective Distress
Related to Restlessness are rated on a 4-point scale from 0 – 3 and are summed yielding a
total score ranging from 0 to 9.
The Global Clinical Assessment of Akathisia uses a 5-point scale ranging from 0 – 4.

(Barnes, 1989, pp. 672-767).
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APPENDIX C – Akathisia Survey
This study has been approved by USM’s IRB.
Protocol number: XXX
You are Invited to Participate
Hello everyone,
My name is Heather Thompson RN, BSN I am a DNP student at The University
of Southern Mississippi. I am doing an evidence-based practice research intervention. My
intervention will include a scenario-based pretest, education on an akathisia scale, and a
scenario-based post-test.
Purpose: The purpose of my project is to bring awareness to akathisia and the
need for an akathisia rating scale. This allows for easy communication of akathisia
symptoms between providers. The scale brings accuracy to the level of severity of
akathisia symptoms before and during treatment.
Description of Study: The study will include healthcare providers at a
Southeastern Mississippi Behavioral Clinic. The providers will be given a scenario-based
case study to test their knowledge of akathisia and the way they narrate their akathisia
findings. Next, the healthcare providers will be educated on akathisia and a rating scale
that will offer a baseline numerical scale for akathisia. A scenario-based case study will
be given as a post-test to implement the akath2isia rating scale and test the knowledge of
the staff.
Benefits: Healthcare providers will benefit from awareness of akathisia and its
scale by having the ability to detect and rate akathisia accurately. This will lead to early
detection and treatment. The akathisia scale will offer transparency of akathisia
symptoms between visits. The level of severity of akathisia symptoms will be
straightforward and to the point.
Confidentiality: Confidentiality will be maintained through a private email.
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Survey
1.

Do you recognize the physical symptoms of akathisia?
a. How do you document your findings of akathisia symptoms?

2.

Do you know what a BARS (Barnes Akathisia Rating Scale) scale are?

3.

How is akathisia evaluated in current patients?

4.

How do you measure the impact of treatment from a visit to a visit?

5.

How often do you see akathisia in your clinic?
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APPENDIX D – Scenario-Based Questionnaire Using the Barnes Akathisia Rating Scale
Scenario #1
A 35-year-old female comes into the office. She is taking Zyprexa 10mg daily.
The patient walks with a steady gait, when the patient stops walking patients’ feet
continue to move in a mild stepping manner. Upon sitting the patient has involuntary
shaking of the lower extremities. The patient states, “I noticed my leg shaking when I sit
but I did not think much of it, I feel fine.” The patient appears to have mild involuntary
leg tremors. How would you explain this patient’s condition and rate the level of severity
using the Barnes Akathisia Rating Scale (BARS)?
Scenario #2
A 20-year-old male has started taking clozapine 12.5mg daily. At the patient's
next visit clozapine dose was increased to 25mg. Over the next few weeks, the patient's
dose gradually increased to 100mg. The patient reports, “I feel restless, I want to relax
but I can’t.” The healthcare provider has the patient rate the severity of their symptoms
on a scale of 1-10. One being nearly no symptoms at all and ten being unbearable
symptoms. The patient states, “If this does not stop, I will not continue taking clozapine. I
rate this feeling of restlessness as an 8/10.” The patient has facial grimacing and appears
irritable. What would you rate the patient’s akathisia score on the Barnes Akathisia
Rating Scale (BARS) akathisia scale?
Scenario #3
A 45- year-old female taking Vraylar 1.5mg daily. Upon taking a seat in the
provider’s office the patient appears uncomfortable, with a mild right leg tremor. The
patient reports, “I feel fine, my leg tremor doesn’t bother me, the medication is working
great.” The patient rates her leg tremor on a scale of 1-10 in severity as a 3. How would
you rate the severity of the patient’s symptoms based on the Barnes Akathisia Rating
Scale (BARS)?
Scenario #4
A 33-year-old-male presents to his doctor’s visit with feelings of increased
agitation and irritability. The patient’s current medication is Abilify 10mg daily, and
Clonidine 0.2mg nightly. The patient reports sleeping well but has a mild foot tremor
during the night that worsens when he awakens. The patient states, the tremors are
bothering him so much so that he would like medication to help him fix this problem.
Rate the patient’s level of severity of akathisia using the Barnes Akathisia Rating Scale
(BARS).
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APPENDIX E – Implementation of an Akathisia Scale into the Initial Mental Health
Assessment PowerPoint® Presentation
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